Fig. 3.

Complement activation products in plasma from controls and atherosclerotic patients with SAP and ACS. Presence of the end product of complement activation, TCC (a), the common complement component for the different pathways, C3bc (b), the activation product for both the classical and lectin pathway, C4bc (c), and the activation product for the alternative pathway, C3bBbP (d) in patients with SAP, ACS and healthy controls. Results are presented as mean ±SEM, n=21-23. e) Presence of activation product C4bc was correlated to IL-1β mRNA expression of controls, ACS and SAP combined, n=66. ACS, acute coronary syndrome; AU, arbitrary unit; C: Complement factor; IL, interleukin; SAP, Stable angina pectoris; TCC, terminal complement complex. ***p<0.001, Bartlett's test for equal variance on log-transformed data with Bonferroni post-tests, (e) Spearman's correlation.